双鹭药业跌2.04%，成交额1.42亿元，主力资金净流出830.96万元

Core Viewpoint - The stock of Shuanglu Pharmaceutical has experienced fluctuations, with a recent decline of 2.04% and a total market capitalization of 7.89 billion yuan, indicating potential volatility in investor sentiment [1]. Financial Performance - For the first half of 2025, Shuanglu Pharmaceutical reported a revenue of 305 million yuan, a year-on-year decrease of 22.24%, while the net profit attributable to shareholders increased significantly by 309.08% to 121 million yuan [2]. - The company has distributed a total of 2.12 billion yuan in dividends since its A-share listing, with 277 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Shuanglu Pharmaceutical increased to 58,500, with an average of 14,564 circulating shares per person, a slight decrease of 1.33% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 8.69 million shares, an increase of 2.34 million shares from the previous period [3].